Macquarie Downgrades Illumina, Citing Headwinds to Sequencing Business | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Macquarie Capital today downgraded Illumina's stock to Underperform, saying the company faces substantial headwinds moving ahead, including cuts in academic and government funding, excess large-scale sequencing capacity, and an "at best" flat microarray business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.